{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:19:28Z","timestamp":1793089168255,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"crossref","award":["2016-0134 2016-0315"],"award-info":[{"award-number":["2016-0134 2016-0315"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["ERC-STG 2015-67242"],"award-info":[{"award-number":["ERC-STG 2015-67242"]}]},{"name":"Crafoord Foundation, Sk\u00e5ne University Hospital, the Scania county, governmental funding of clinical research within the Swedish National Health Service","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Governmental funding of clinical research within the Swedish National Health Service","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["Linnaeus grant Dnr 349-2006-237, Strategic Research Area Exodiab Dnr 2009-103"],"award-info":[{"award-number":["Linnaeus grant Dnr 349-2006-237, Strategic Research Area Exodiab Dnr 2009-103"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"crossref","award":["Dnr IRC15-0067"],"award-info":[{"award-number":["Dnr IRC15-0067"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Long term \u03b2-blocker therapy after myocardial infarction (MI) reduces mortality and recurrent MI but evidence for this treatment predates contemporary acute coronary care. \u03b2-blocker treatment is a key quality of care indicator in the Swedish national quality register for acute coronary care, Riks-HIA. Between 2011 and 2015 a declining number of MI-patients discharged with a \u03b2-blocker from the coronary care unit (CCU) at Helsingborg and other hospitals was reported. This retrospective observational study aimed to investigate the causes for discharge without a \u03b2-blocker and relate it to outcome, compared to patients discharged with a \u03b2-blocker.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>MI-patients registered in Riks-HIA discharged without \u03b2-blocker during 2011\u20132015 (no-\u03b2-group) and a control group (\u03b2-group) comprised of patients discharged with \u03b2-blocker treatment between January 1 to December 31, 2013, were matched by RIKS-HIA criteria for \u03b2-blocker use. Clinical characteristics, date of death, readmission for MI, other cardiovascular events were collected from Riks-HIA and medical records.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The no-\u03b2-group included 141 patients, where 65.2% had a justified reason for non-\u03b2-blocker use. The \u03b2-group included 206 patients. There was no difference in cardiovascular risk factor profile. There were a trend towards a higher number of readmissions for MI in the no-\u03b2-group was (<jats:italic>n<\/jats:italic>\u2009=\u20098 (5.7%) vs <jats:italic>n<\/jats:italic>\u2009=\u20092 (1.0%), <jats:italic>p<\/jats:italic>\u2009=\u20090.02), but not mortality (6 (4.3%) vs 2 (1.0%), <jats:italic>p<\/jats:italic>\u2009=\u20090.07) and combined readmission for angina pectoris, heart failure, arrhythmias or stroke\/TIA (<jats:italic>n<\/jats:italic>\u2009=\u200923 (16.3%) vs <jats:italic>n<\/jats:italic>\u2009=\u200925 (12.1%), <jats:italic>p<\/jats:italic>\u2009=\u20090.27).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>A majority of the patients in the no-\u03b2-group had a justified absence of a \u03b2-blocker. \u03b2-blocker treatment post-MI showed a trend towards fewer readmissions for MI. But important quality information is lacking to make a firm conclusion of the effect on outcome.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01441-0","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T19:02:47Z","timestamp":1586458967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u03b2-blockers after myocardial infarction and 1-year clinical outcome \u2013 a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Tora","family":"Hagsund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Erik","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gustav","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Madsen Hardig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"issue":"5","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335\u201371.","journal-title":"Prog Cardiovasc Dis"},{"key":"1441_CR2","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Collaborators (907) CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39."},{"issue":"21","key":"1441_CR3","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"EM Antman","year":"2008","unstructured":"Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess improvement in therapeutic outcomes by optimizing platelet InhibitioN with Prasugrel-thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1441_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"1441_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/archinte.160.7.947","volume":"160","author":"J Chen","year":"2000","unstructured":"Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160(7):947\u201352.","journal-title":"Arch Intern Med"},{"issue":"9","key":"1441_CR6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.amjcard.2010.06.048","volume":"106","author":"N Ozasa","year":"2010","unstructured":"Ozasa N, Kimura T, Morimoto T, Hou H, Tamura T, Shizuta S, et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol. 2010;106(9):1225\u201333.","journal-title":"Am J Cardiol"},{"issue":"6","key":"1441_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcin.2013.12.206","volume":"7","author":"JH Yang","year":"2014","unstructured":"Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interventions. 2014;7(6):592\u2013601.","journal-title":"JACC Cardiovasc Interventions"},{"issue":"11","key":"1441_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.amjcard.2015.02.057","volume":"115","author":"BT Huang","year":"2015","unstructured":"Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between Oral beta-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015;115(11):1529\u201338.","journal-title":"Am J Cardiol"},{"issue":"20","key":"1441_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"issue":"22","key":"1441_CR10","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith Jr","year":"2011","unstructured":"Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458\u201373.","journal-title":"Circulation"},{"issue":"3","key":"1441_CR11","first-page":"267","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 2016;37(3):267\u2013315.","journal-title":"Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)"},{"key":"1441_CR12","first-page":"120","volume-title":"Nationella riktlinjer f\u00f6r hj\u00e4rtsjukv\u00e5rd","author":"Socialstyrelsen","year":"2015","unstructured":"Socialstyrelsen. Nationella riktlinjer f\u00f6r hj\u00e4rtsjukv\u00e5rd; 2015. p. 120."},{"key":"1441_CR13","first-page":"34","volume-title":"Akut kransk\u00e4rlssjukdom Rekommendationer f\u00f6r bed\u00f6mning, behandling och sekund\u00e4rprevention [Internet]. Svenska Kardiologf\u00f6reningen","author":"S Koul","year":"2015","unstructured":"Koul S, Hagstr\u00f6m E, Smith G. Akut kransk\u00e4rlssjukdom Rekommendationer f\u00f6r bed\u00f6mning, behandling och sekund\u00e4rprevention [Internet]. Svenska Kardiologf\u00f6reningen; 2015. p. 34. Available from: http:\/\/www.cardio.se\/nationella-riktlinjer."},{"issue":"13","key":"1441_CR14","first-page":"672","volume":"109","author":"T Jernberg","year":"2012","unstructured":"arbetsgrupp: FR-Hs, Jernberg T, Bergstr\u00f6m O, Held C, Johanson P, Kellerth T, et al. Riks-HIA ska ta fram nytt index f\u00f6r omr\u00e5den med f\u00f6rb\u00e4ttringsutrymme. L\u00e4kartidningen. 2012;109(13):672\u20133.","journal-title":"L\u00e4kartidningen"},{"key":"1441_CR15","volume-title":"Hur tas RIKS-HIA:s kvalitetsindex fram?","author":"SWEDEHEART","year":"2016","unstructured":"SWEDEHEART. Hur tas RIKS-HIA:s kvalitetsindex fram?. 2016 [2016 May]. Available from: http:\/\/www.ucr.uu.se\/swedeheart\/index.php\/nyheter\/137-hur-tas-riks-hias-kvalitetsindex-fram."},{"key":"1441_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/B978-1-4377-0398-6.00054-8","volume-title":"Braunwald's heart disease a textbook of cardiovascular medicine. 2","author":"EM Antman","year":"2012","unstructured":"Antman EM. ST-segment elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Bonow RO, Mann DM, Zipes DP, Libby P, Braunwald E, editors. Braunwald's heart disease a textbook of cardiovascular medicine. 2. 9th ed. Philadelphia: Elsevier Saunders; 2012. p. 1087\u2013110.","edition":"9"},{"key":"1441_CR17","volume-title":"Bonferroni Correction [Internet]. MathWorld - A Wolfram Web Resource","author":"WW Eric","year":"2016","unstructured":"Eric W W. Bonferroni Correction [Internet]. MathWorld - A Wolfram Web Resource 2016 [2016 May 22]. Available from: http:\/\/mathworld.wolfram.com\/BonferroniCorrection.html."},{"issue":"2","key":"1441_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12928-012-0137-9","volume":"28","author":"B Bao","year":"2013","unstructured":"Bao B, Ozasa N, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, et al. Beta-blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther. 2013;28(2):139\u201347.","journal-title":"Cardiovasc Interv Ther"},{"issue":"6","key":"1441_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/heartjnl-2013-305137","volume":"100","author":"EH Choo","year":"2014","unstructured":"Choo EH, Chang K, Ahn Y, Jeon DS, Lee JM, Kim DB, et al. Benefit of beta-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention. Heart. 2014;100(6):492\u20139.","journal-title":"Heart"},{"issue":"6","key":"1441_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.amjcard.2005.05.025","volume":"96","author":"G De Luca","year":"2005","unstructured":"De Luca G, de Boer MJ, Ottervanger JP, van\u2019t Hof AW, Hoorntje JC, Gosselink AT, et al. Impact of beta-blocker therapy at discharge on long-term mortality after primary angioplasty for ST-segment elevation myocardial infarction. Am J Cardiol. 2005;96(6):806\u20139.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1441_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1034\/j.1600-6143.2003.08062.x","volume":"16","author":"K Ellis","year":"2003","unstructured":"Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the epic, epilog, Epistent, capture and rapport trials. J Interv Cardiol. 2003;16(4):299\u2013305.","journal-title":"J Interv Cardiol"},{"issue":"10","key":"1441_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.jacc.2003.09.071","volume":"43","author":"SJ Kernis","year":"2004","unstructured":"Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43(10):1773\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1441_CR23","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1253\/circj.CJ-10-1241","volume":"75","author":"M Konishi","year":"2011","unstructured":"Konishi M, Haraguchi G, Yoshikawa S, Kimura S, Inagaki H, Isobe M. Additive effects of beta-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circul J. 2011;75(8):1982\u201391.","journal-title":"Circul J"},{"issue":"4","key":"1441_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjcard.2012.10.026","volume":"111","author":"D Nakatani","year":"2013","unstructured":"Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol. 2013;111(4):457\u201364.","journal-title":"Am J Cardiol"},{"key":"1441_CR25","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno Hc, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","DOI":"10.1002\/ejhf.592"},{"key":"1441_CR26","first-page":"401","volume-title":"Svensk kardiologi - en historiebok","author":"B Lindahl","year":"2014","unstructured":"Lindahl B. Guldgruvan i svensk kardiologi - Svenska kardiologiska kvalitetsregister. In: Kardiologf\u00f6reningen S, editor. Svensk kardiologi - en historiebok. M\u00f6lndal: Svenska kardiologf\u00f6reningen; 2014. p. 401\u201313."},{"issue":"4","key":"1441_CR27","doi-asserted-by":"publisher","first-page":"e004678","DOI":"10.1161\/CIRCOUTCOMES.118.004678","volume":"11","author":"DT Ko","year":"2018","unstructured":"Ko DT, Jackevicius CA. Stopping beta-Blockers After Myocardial Infarction: Not So Fast! Circ Cardiovasc Qual Outcomes. 2018;11(4):e004678.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1441_CR28","unstructured":"Jernberg T. Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART). ClinicalTrials.gov identifier: NCT03278509."},{"key":"1441_CR29","first-page":"221","volume-title":"Korrelation och regression. Statistik f\u00f6r h\u00e4lsovetenskaperna","author":"G Eljertsson","year":"2012","unstructured":"Eljertsson G. Korrelation och regression. Statistik f\u00f6r h\u00e4lsovetenskaperna. 2nd ed. Lund: Studentlitteratur AB; 2012. p. 221\u201350.","edition":"2"},{"key":"1441_CR30","first-page":"459","volume-title":"Kardiovaskul\u00e4r medicin","author":"P MNilsson","year":"2010","unstructured":"MNilsson P. Kardiovaskul\u00e4ra riskfaktorer, prim\u00e4r och sekund\u00e4r prevention. In: Fundin B, editor. Kardiovaskul\u00e4r medicin. Stockholm: Liber AB; 2010. p. 459\u201375."},{"issue":"7200","key":"1441_CR31","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical research ed). 1999;318(7200):1730\u20137.","journal-title":"BMJ (Clinical research ed)"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01441-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-020-01441-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01441-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:07:57Z","timestamp":1617923277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01441-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01441-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed by the first author, within the medical education and since the study was a quality work regarding given treatment recommended in national Swedish and European guidelines, ethical approval is not needed [\u2013]. All patients gave written and verbal informed consent to participate in the Riks-HIA and SCAAR registries at the time at their admission at the coronary unit or at the coronary catheterization laboratory. Hence Application for ethical approval from the local Swedish Ethical Review Authority at Lund University, was thereby waived (Dnr 2017\/885).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have given written and verbal informed consent to participate in the Riks-HIA and SCAAR registries, which includes the approval for analysis of the data and publication in scientific journals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}